ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
Recently Viewed
You have not visited any articles yet, Please visit some articles to see contents here.

Figure 1Loading Img

Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics

View Author Information
Department of Biochemistry and Department of Organic Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
*C.N.: phone, (41) 446353945; fax, (41) 446353948; e-mail, [email protected]. A.C.: phone, (41) 446355521; fax, (41) 446356862; e-mail, [email protected]
Cite this: ACS Med. Chem. Lett. 2012, 3, 10, 834–838
Publication Date (Web):August 23, 2012
Copyright © 2012 American Chemical Society
Article Views
Read OnlinePDF (1 MB)
Supporting Info (1)»


Abstract Image

We have discovered a novel chemical class of inhibitors of the EphB4 tyrosine kinase by fragment-based high-throughput docking followed by explicit solvent molecular dynamics simulations for assessment of the binding mode. The synthesis of a single derivative (compound 7) of the hit identified in silico has resulted in an improvement of the inhibitory potency in an enzymatic assay from 8.4 μM to 160 nM and a ligand efficiency of 0.39 kcal/mol per non-hydrogen atom. Such remarkable improvement in affinity is due to an additional hydroxyl group involved in two favorable (buried) hydrogen bonds as predicted by molecular dynamics and validated by the crystal structure of the complex with EphA3 solved at 1.7 Å resolution.

Supporting Information

Jump To

Chemical synthesis, crystallization, similarity comparison with known Eph inhibitors, description of the algorithm used to decompose a compound library, distribution of physicochemical properties of the library of anchor fragments, and MD screening of candidate compounds. This material is available free of charge via the Internet at

Accession Codes

The atomic coordinates and structure factors of EphA3 in complex with compound 7 have been deposited with the Protein Data Bank as entry 4G2F.

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

Cited By

This article is cited by 35 publications.

  1. Andrea Unzue, Hongtao Zhao, Graziano Lolli, Jing Dong, Jian Zhu, Melanie Zechner, Aymeric Dolbois, Amedeo Caflisch, and Cristina Nevado . The “Gatekeeper” Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains. Journal of Medicinal Chemistry 2016, 59 (7) , 3087-3097.
  2. Min Xu, Andrea Unzue, Jing Dong, Dimitrios Spiliotopoulos, Cristina Nevado, and Amedeo Caflisch . Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics. Journal of Medicinal Chemistry 2016, 59 (4) , 1340-1349.
  3. Jing Dong, Hongtao Zhao, Ting Zhou, Dimitrios Spiliotopoulos, Chitra Rajendran, Xiao-Dan Li, Danzhi Huang, and Amedeo Caflisch . Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases. ACS Medicinal Chemistry Letters 2015, 6 (1) , 79-83.
  4. Yuri Pevzner, Emilie Frugier, Vinushka Schalk, Amedeo Caflisch, and H. Lee Woodcock . Fragment-Based Docking: Development of the CHARMMing Web User Interface as a Platform for Computer-Aided Drug Design. Journal of Chemical Information and Modeling 2014, 54 (9) , 2612-2620.
  5. Andrea Unzue, Jing Dong, Karine Lafleur, Hongtao Zhao, Emilie Frugier, Amedeo Caflisch, and Cristina Nevado . Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation. Journal of Medicinal Chemistry 2014, 57 (15) , 6834-6844.
  6. Igor José dos Santos Nascimento, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva-Júnior. Repurposing FDA-approved Drugs Targeting SARS-CoV2 3CL pro : A Study by Applying Virtual Screening, Molecular Dynamics, MM-PBSA Calculations and Covalent Docking. Letters in Drug Design & Discovery 2022, 19 (7) , 637-653.
  7. Miao-Miao Wang, Ya-Nan Li, Wei-Kang Ming, Pan-Feng Wu, Ping Yi, Zi-Peng Gong, Xiao-Jiang Hao, Chun-Mao Yuan. Bioassay-guided isolation of human carboxylesterase 2 inhibitory and antioxidant constituents from Laportea bulbifera: Inhibition interactions and molecular mechanism. Arabian Journal of Chemistry 2022, 15 (4) , 103723.
  8. Caiying Zhang, Yuelong Li, Abdus Samad, Peiyi Zheng, Zheng Ji, Feng Chen, Huidong Zhang, Tengchuan Jin. Structure and mutation analysis of the hexameric P4 from Pseudomonas aeruginosa phage phiYY. International Journal of Biological Macromolecules 2022, 194 , 42-49.
  9. Moira Rachman, Serena Piticchio, Maciej Majewski, Xavier Barril. Fragment-to-lead tailored in silico design. Drug Discovery Today: Technologies 2021, 40 , 44-57.
  10. Azizeh Abdolmaleki, Fereshteh Shiri, Jahan B. Ghasemi. Use of Molecular Docking as a Decision-Making Tool in Drug Discovery. 2021, 229-243.
  11. Andrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, Eugenio Gaudio, Chiara Tarantelli, Jing Dong, Hongtao Zhao, Johanna Pachmayr, Stefan Zahler, Elena Bernasconi, Giulio Sartori, Luciano Cascione, Francesco Bertoni, Paweł Śledź, Amedeo Caflisch, Cristina Nevado. Understanding the mechanism of action of pyrrolo[3,2- b ]quinoxaline-derivatives as kinase inhibitors. RSC Medicinal Chemistry 2020, 11 (6) , 665-675.
  12. V. D. Dyachenko, S. M. Sukach, A. S. Morkovnik. 2-Acylcycloalkanones in Organic Synthesis. Russian Journal of Organic Chemistry 2020, 56 (6) , 949-973.
  13. Yoel Rodríguez, Guillermo Gerona‐Navarro, Roman Osman, Ming‐Ming Zhou. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4. Proteins: Structure, Function, and Bioinformatics 2020, 88 (3) , 414-430.
  14. Matteo Incerti, Simonetta Russo, Miriam Corrado, Carmine Giorgio, Vigilio Ballabeni, Paola Chiodelli, Marco Rusnati, Laura Scalvini, Donatella Callegari, Riccardo Castelli, Federica Vacondio, Francesca Ferlenghi, Massimiliano Tognolini, Alessio Lodola. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. European Journal of Medicinal Chemistry 2020, 189 , 112083.
  15. Zarko Gagic, Dusan Ruzic, Nemanja Djokovic, Teodora Djikic, Katarina Nikolic. In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. Frontiers in Chemistry 2020, 7
  16. Süleyman Selim Çınaroğlu, Emel Timuçin. Insights into an alternative benzofuran binding mode and novel scaffolds of polyketide synthase 13 inhibitors. Journal of Molecular Modeling 2019, 25 (5)
  17. Jia-Hau Lee, Wei-Chen Lin, Tsung-Kai Wen, Chihuei Wang, Ying-Ting Lin. Inhibiting two cellular mutant epidermal growth factor receptor tyrosine kinases by addressing computationally assessed crystal ligand pockets. Future Medicinal Chemistry 2019, 11 (8) , 833-846.
  18. Yuanyuan Shan, Binghe Wang, Jie Zhang. New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. Medicinal Research Reviews 2018, 38 (5) , 1674-1705.
  19. Chen Wang, Pan Xu, Luyu Zhang, Jing Huang, Kongkai Zhu, Cheng Luo. Current Strategies and Applications for Precision Drug Design. Frontiers in Pharmacology 2018, 9
  20. Paweł Śledź, Amedeo Caflisch. Protein structure-based drug design: from docking to molecular dynamics. Current Opinion in Structural Biology 2018, 48 , 93-102.
  21. Lucia Sessa, Simona Concilio, Stefano Piotto. Molecular Dynamics and Morphing Protocols for High Accuracy Molecular Docking. 2018, 85-96.
  22. Samanth Reddy Kedika, D. Gomika Udugamasooriya. Converting a weaker ATP-binding site inhibitor into a potent hetero-bivalent ligand by tethering to a unique peptide sequence derived from the same kinase. Organic & Biomolecular Chemistry 2018, 16 (35) , 6443-6449.
  23. Damian W Young. Using Fragment Based Drug Discovery to Target Epigenetic Regulators in Cancer. MOJ Bioequivalence & Bioavailability 2017, 4 (1)
  24. Maria Maddalena Cavalluzzi, Giuseppe Felice Mangiatordi, Orazio Nicolotti, Giovanni Lentini. Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. Expert Opinion on Drug Discovery 2017, 12 (11) , 1087-1104.
  25. Mikhail Krasavin. N-(Hetero)aryl-2-imidazolines: an emerging privileged motif for contemporary drug design. Chemistry of Heterocyclic Compounds 2017, 53 (3) , 240-255.
  26. Na Zhang, Hongtao Zhao. Enriching screening libraries with bioactive fragment space. Bioorganic & Medicinal Chemistry Letters 2016, 26 (15) , 3594-3597.
  27. Andrea Unzue, Karine Lafleur, Hongtao Zhao, Ting Zhou, Jing Dong, Peter Kolb, Johanna Liebl, Stefan Zahler, Amedeo Caflisch, Cristina Nevado. Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. European Journal of Medicinal Chemistry 2016, 112 , 347-366.
  28. Dimitrios Spiliotopoulos, Amedeo Caflisch. Fragment-based in silico screening of bromodomain ligands. Drug Discovery Today: Technologies 2016, 19 , 81-90.
  29. Hongtao Zhao, Amedeo Caflisch. Current kinase inhibitors cover a tiny fraction of fragment space. Bioorganic & Medicinal Chemistry Letters 2015, 25 (11) , 2372-2376.
  30. Hongtao Zhao, Amedeo Caflisch. Molecular dynamics in drug design. European Journal of Medicinal Chemistry 2015, 91 , 4-14.
  31. Guo-Bo Li, Ling-Ling Yang, Yiming Yuan, Jun Zou, Yu Cao, Sheng-Yong Yang, Rong Xiang, Mingli Xiang. Virtual screening in small molecule discovery for epigenetic targets. Methods 2015, 71 , 158-166.
  32. Hongtao Zhao, Lisa Gartenmann, Jing Dong, Dimitrios Spiliotopoulos, Amedeo Caflisch. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. Bioorganic & Medicinal Chemistry Letters 2014, 24 (11) , 2493-2496.
  33. Danzhi Huang, Emanuele Rossini, Sandra Steiner, Amedeo Caflisch. Structured Water Molecules in the Binding Site of Bromodomains Can Be Displaced by Cosolvent. ChemMedChem 2014, 9 (3) , 573-579.
  34. Hongtao Zhao, Amedeo Caflisch. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk. Bioorganic & Medicinal Chemistry Letters 2014, 24 (6) , 1523-1527.
  35. Hongtao Zhao, Amedeo Caflisch. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. Bioorganic & Medicinal Chemistry Letters 2013, 23 (20) , 5721-5726.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect

This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. Read the ACS privacy policy.